BYSI 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• SEED was founded by us in 2019. Since then, Eli Lilly participated in SEED’s Series A-2 financing in 2020 and Eisai Co., Ltd. (“Eisai”) participated in SEED’s Series A-3 financing in 2024. SEED is utilizing a proprietary Targeted Protein Degradation (TPD) drug discovery platform, or “molecular glue”…

• share-based compensation to employees, directors and non-employee consultants; and

• The following table summarizes the results of our operations for the three months ended June 30, 2026 and 2025, respectively, together with the percentage changes in those items:

• Research and development (R&D) expenses were $1.0 million for the three months ended June 30, 2026, compared to $1.0 million for the three months ended June 30, 2025. R&D expenses remained relatively flat, as a $0.3 million increase in drug manufacturing activities to prepare for potential future st…

• The following table summarizes the research and development expenses for the three months ended June 30, 2026 and 2025:

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• Management’s Discussion and Analysis of Financial Condition and Results of Operations

• SEED was founded by us in 2019. As of March 31, 2026, BeyondSpring Inc. and SEED Technology Limited, its majority-owned indirect subsidiary, or, collectively, the BYSI Entities, owned an aggregate of 10,289,545 Series A-1 Preferred Shares of SEED.

• Comparison of the Three Months Ended March 31, 2026 and 2025

• The following table summarizes the results of our operations for the three months ended March 31, 2026 and 2025, respectively, together with the percentage changes in those items:

• Research and development (R&D) expenses were $1.1 million for the three months ended March 31, 2026 compared to $0.9 million for the three months ended March 31, 2025. The $0.2 million increase was primarily driven by expanded drug manufacturing activities to prepare for potential future study initi…

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• Risks Related to Our Financial Position and Need for Additional Capital

• We will depend on our ability to obtain necessary financing to fund our working capital requirement to continue as a going concern.

• We are a clinical stage global biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. We have incurred operating losses and negative cash flows from operations since our inception. We have devoted most of our fina…

• Our future success depends on our ability to retain our Chief Executive Officer and other key executives and to attract, retain and motivate qualified personnel.

• We are highly dependent on our senior management team and other key personnel. Effective July 1, 2026, Mr. Min Qiu began serving as our Chief Executive Officer in connection with a leadership transition. While we believe this transition supports continuity in the management of our business, the loss…